Your Messages Inbox
Your Article Summary
See Latest ArticlesARIAD Announces Result of First Interim Analysis of Phase 3 Succeed Trial of Oral Ridaforolimus, Its Investigational mTOR Inhibitor, in Metastatic Sarcomas
ARIAD Pharmaceuticals, 09/15/09
ARIAD Pharmaceuticals, Inc. announced that the independent Data Monitoring Committee of the Phase 3 SUCCEED trial has completed the first interim efficacy analysis as specified by the study protocol and has recommended that the randomized, placebo–controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to full patient enrollment and completion. The DMC made this recommendation after reviewing the pre–specified statistical analyses and available data on the safety and efficacy of oral ridaforolimus.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09
Article Search
Sponsor